M-Vpr-X4-tropic NL4-3, or (C) infected in the presence of 10 μg/ml SP4-2, or (D) infected in the presence of 250 nM AMD3100. In a parallel experiment, SupT1 cells (1 × 10) were either (E) mock infected, or (F) infected for 2 h at 0.5 moi with BlaM-Vpr-X4-tropic NL4-3, or (G) infected in the presence of 20 ng/ml sCD4, or (H) infected in the presence of 20 ng/ml sCD4 together with 16 μg/ml SP4-2. Cells were loaded with CCF2/AM dye and fusion was analyzed by multiparameter flow cytometry using a violet laser for excitation of CCF, and gated from 10,000 cells. Percentages in each panel are of cells displaying blue fluorescence (virus fusion positive cells). Representative of 3 separate experiments.<p><b>Copyright information:</b></p><p>Taken fr...
International audienceThe HIV-1 auxiliary protein Vpr and Vpr-fusion proteins can be copackaged with...
Bsequently added to C8166 T-cells. Alternatively, T-cells were pretreated with AMD3100, enfuvirtide,...
<p>A and B) Effect of soluble recombinant CCR5-T4L or CCL5 on macrophages using cell-cell fusion ass...
Incubated at 37°C in COatmosphere with increasing concentrations of SP4-2, as indicated, then infect...
10M ddC, or mock treated (0 μg SP4-2), as indicated. Then, cells were infected with HIV-1 (NL4-3) at...
10M ddC, or mock treated (0 μg SP4-2), as indicated. Then, cells were infected with HIV-1 (NL4-3) at...
Tmosphere with increasing concentrations of SP4-2 for 1.5 hours prior to infection. Treatment was wa...
1 chimera NL4-3 EnvLuc/VSV-G pseudotype, washed 3 times, and then treated with increasing concentrat...
Fusion of HIV with its host cell requires the interaction of the viral envelope glycoprotein 120 (gp...
<p><b>(A)</b> Relative infectivity of an HIV-1 GFP-reporter virus without any label (Control) or wit...
<p>A) HIV-1 viral fusion in PSC-macrophages. The percentage of fusion of HIV-1 virions was normalise...
<p>A1. MDM treated with CAP or helium (control) were analyzed by flow cytometry for expression of CC...
Topical blockade of the gp41 fusogenic protein of HIV-1 is one possible strategy by which microbicid...
<p>(A) Titration of PF74 or indicated derivatives onto HeLa cells infected with VSV-G pseudotyped GF...
Background: The gene therapeutic Cal-1 comprises the anti-HIV agents: (i) sh5, a short hairpin RNA t...
International audienceThe HIV-1 auxiliary protein Vpr and Vpr-fusion proteins can be copackaged with...
Bsequently added to C8166 T-cells. Alternatively, T-cells were pretreated with AMD3100, enfuvirtide,...
<p>A and B) Effect of soluble recombinant CCR5-T4L or CCL5 on macrophages using cell-cell fusion ass...
Incubated at 37°C in COatmosphere with increasing concentrations of SP4-2, as indicated, then infect...
10M ddC, or mock treated (0 μg SP4-2), as indicated. Then, cells were infected with HIV-1 (NL4-3) at...
10M ddC, or mock treated (0 μg SP4-2), as indicated. Then, cells were infected with HIV-1 (NL4-3) at...
Tmosphere with increasing concentrations of SP4-2 for 1.5 hours prior to infection. Treatment was wa...
1 chimera NL4-3 EnvLuc/VSV-G pseudotype, washed 3 times, and then treated with increasing concentrat...
Fusion of HIV with its host cell requires the interaction of the viral envelope glycoprotein 120 (gp...
<p><b>(A)</b> Relative infectivity of an HIV-1 GFP-reporter virus without any label (Control) or wit...
<p>A) HIV-1 viral fusion in PSC-macrophages. The percentage of fusion of HIV-1 virions was normalise...
<p>A1. MDM treated with CAP or helium (control) were analyzed by flow cytometry for expression of CC...
Topical blockade of the gp41 fusogenic protein of HIV-1 is one possible strategy by which microbicid...
<p>(A) Titration of PF74 or indicated derivatives onto HeLa cells infected with VSV-G pseudotyped GF...
Background: The gene therapeutic Cal-1 comprises the anti-HIV agents: (i) sh5, a short hairpin RNA t...
International audienceThe HIV-1 auxiliary protein Vpr and Vpr-fusion proteins can be copackaged with...
Bsequently added to C8166 T-cells. Alternatively, T-cells were pretreated with AMD3100, enfuvirtide,...
<p>A and B) Effect of soluble recombinant CCR5-T4L or CCL5 on macrophages using cell-cell fusion ass...